Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Goldman, Jonathan; Garassino, Marina; Chen, Yuanbin; ÖZGÜROĞLU, Mustafa; Dvorkin, Mikhail; Trukhin, Dmytro; Statsenko, Galina; Hotta, Katsuyuki; Ji, Jun; Hochmair, Maximilian; Voitko, Oleksandr; Havel, Libor; Poltoratskiy, Artem; Losonczy, Gyorgy; Reinmuth, Niels; Patel, Nikunj; Laud, Peter; Shire, Norah; Jiang, Haiyi; Paz-Ares, Luis

doi:10.1016/j.lungcan.2020.09.003

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study

Goldman J. W., Garassino M. C., Chen Y., ÖZGÜROĞLU M., Dvorkin M., Trukhin D., ...Daha Fazla

LUNG CANCER, cilt.149, ss.46-52, 2020 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 149
Basım Tarihi: 2020
Doi Numarası: 10.1016/j.lungcan.2020.09.003
Dergi Adı: LUNG CANCER
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Sayfa Sayıları: ss.46-52
İstanbul Üniversitesi Adresli: Hayır

Özet

Objectives: In the phase III CASPIAN study, first-line durvalumab plus etoposide in combination with either cisplatin or carboplatin (EP) significantly improved overall survival (primary endpoint) versus EP alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) at the interim analysis. Here we report patient-reported outcomes (PROs).